1531P Evaluating autoimmune diseases as exclusion criteria in immuno-oncology trials
Silvia Metelli(Roche (Switzerland)), S. Rizzo(Kaiser Permanente South San Francisco Medical Center), Thanh G.N. Ton(Public Health – Seattle & King County), P. Wen(Shandong University), Ning Ma(Drug Safety Research Unit), Anja Knott(Roche (United Kingdom)), Bogdana Balas(Roche (Switzerland)), Lindsay C Thompson(MRC Clinical Trials Unit at UCL)
Cited by 0
Related Papers
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
|The Lancet|2007|570
The Epidemiology of Narcolepsy
|SLEEP|2007|446